Latest intangible assets for CBAY: $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Cymabay Therapeutics's intangible assets stands at $0 as of December 2023. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Cymabay Therapeutics reported $0 in intangible assets versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
In the prior-year period, the figure was $0. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Cymabay Therapeutics's intangible assets evolved across reporting periods, while the comparison chart places CBAY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, intangible assets is commonly used to spot outliers. Cymabay Therapeutics's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.